Estrogen Dominance: Causes, Testing & Treatment Evidence

A Diagnosis the Medical Mainstream Debates — But the Biology Is Real

"Estrogen dominance" as a formal diagnosis does not appear in the DSM-5, ICD-11, or any major endocrine society guideline — yet the concept captures a real and clinically meaningful phenomenon: an imbalance between estrogen and progesterone levels in which estrogen's biological effects outweigh progesterone's counterbalancing influence. The term was popularized by physician John Lee in the 1990s and has since become a central concept in integrative and functional medicine approaches to women's hormonal health.

The concept matters because estrogen and progesterone don't simply act independently — they modulate each other's receptor expression and downstream effects. Progesterone downregulates estrogen receptors and upregulates 17β-hydroxysteroid dehydrogenase, an enzyme that converts potent estradiol (E2) to the weaker estrone (E1). When progesterone is relatively deficient, this modulation fails, amplifying estrogen's proliferative effects on breast, uterine, and adipose tissue.

Causes and Contributing Factors

Relative estrogen dominance arises through multiple pathways. Anovulatory cycles — common in perimenopause, PCOS, and high-stress states — produce estrogen without the progesterone surge that follows ovulation (since progesterone is primarily produced by the corpus luteum). This is the most straightforward cause: absent ovulation means absent progesterone production, leaving estrogen unopposed for that cycle.

• Anovulation: no corpus luteum, no progesterone; common in PCOS, perimenopause, excessive exercise
• Aromatase excess: adipose tissue converts androgens to estrogen via aromatase; obesity substantially elevates circulating estrogen in both sexes
• Impaired liver clearance: the liver detoxifies estrogens via Phase I hydroxylation and Phase II glucuronidation/sulfation; liver disease or nutrient deficiencies can impair this
• Gut dysbiosis (estrobolome): certain gut bacteria produce beta-glucuronidase, which deconjugates excreted estrogens in the bowel, allowing reabsorption — termed enterohepatic recirculation
• Xenoestrogen exposure: exogenous compounds that bind or activate estrogen receptors

Xenoestrogens: Compounds, Mechanisms, and Exposure Routes

Xenoestrogens are synthetic or natural compounds that mimic or modulate estrogenic activity by binding to estrogen receptors alpha or beta. The most studied classes are bisphenol compounds, phthalates, organochlorine pesticides, and phytoestrogens.

The "cocktail effect" — cumulative exposure to multiple low-dose xenoestrogens — is a genuine regulatory concern. Individual compounds may fall below observable-effect levels while combined exposure exceeds biological significance. This is particularly relevant for developing fetuses and children, whose receptor sensitivity and metabolic clearance differ from adults.

DIM Supplementation: What the Evidence Shows

Diindolylmethane (DIM) is a compound formed in the gut from indole-3-carbinol (I3C), which is produced when cruciferous vegetables — broccoli, Brussels sprouts, cauliflower — are chewed and enzymatically processed. DIM modulates estrogen metabolism by promoting the 2-hydroxylation pathway over the 16α-hydroxylation pathway. The 2-hydroxyestrone (2-OHE1) metabolite is considered biologically weak and potentially protective; 16α-hydroxyestrone (16α-OHE1) is more estrogenic and has been associated in some studies with breast cancer risk, though this "2:16 ratio" hypothesis remains controversial.

Human clinical trial data for DIM supplementation are limited. A 2012 randomized trial in 130 postmenopausal women taking tamoxifen found DIM 150 mg/day shifted the urinary 2-OHE1:16α-OHE1 ratio favorably. Studies in premenopausal women with risk factors for breast cancer have shown similar metabolite shifts at doses of 108–300 mg/day. Whether shifting this metabolite ratio actually reduces cancer risk has not been confirmed in prospective outcome trials — a critical gap.

Testing Methods: Saliva, Blood, and Urine Compared

Accurate hormonal assessment is essential before treatment decisions, and the testing method significantly affects results and interpretation. No single method is universally superior; choice depends on the clinical question.

• Serum (blood): the standard; measures total hormone; estradiol and progesterone reference ranges are well-established; timing within cycle is critical for accuracy
• Saliva: measures free (unbound) hormone; advocated for bioavailable fraction; significant variability from food contamination, collection timing, and blood in saliva; not recommended by most endocrinology societies for routine diagnosis
• Dried urine (DUTCH test): measures hormone metabolites over 24-hour collection windows; provides insight into estrogen metabolism pathways (2-OH vs. 16α-OH), adrenal function, and cortisol rhythm; gaining adoption in functional medicine; not validated against clinical outcomes for most indications

The DUTCH (Dried Urine Test for Comprehensive Hormones) test from Precision Analytical is commercially popular but occupies a gray zone: its metabolite data is real and technically valid, but interpretation frameworks and reference ranges are not yet supported by the same body of clinical outcome research that backs serum testing. Using DUTCH data to guide hormone dosing decisions remains evidence-poor.

This article is for informational purposes only. Consult a qualified healthcare professional.